Koers Biodexa Pharmaceuticals Plc London S.E.
Aandelen
BDRX
GB00BNGF1L75
Biotechnologie & Medisch Onderzoek
Omzet 2023 * | 298K 376K 349K | Omzet 2024 * | - | Marktkapitalisatie | 1,78 mln. 2,25 mln. 2,08 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | 5,98 x |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-
| K/w-verhouding 2024 * |
-
| Werknemers | 27 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 57,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vincent Holmes
COO | Chief Operating Officer | - | - |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29-10-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,56% | 108 mld. | |
+10,02% | 104 mld. | |
+7,22% | 23,66 mld. | |
-11,91% | 22,1 mld. | |
-3,29% | 19,71 mld. | |
-35,98% | 18,2 mld. | |
-14,02% | 16,19 mld. | |
+4,61% | 13,72 mld. | |
+35,05% | 12,22 mld. |